HIV/AIDS Therapy
Sustiva provides immunosuppressed HIV/AIDS patients effective treatment alternative
Published in AIDS Weekly, September 2nd, 2002
Data presented at the XIV International AIDS Conference show that a greater proportion of patients on highly active antiretroviral therapy (HAART) containing Sustiva (efavirenz), Bristol-Myers Squibb's (BMY) once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI), achieved a viral load less than 400 copies/mL and CD4 cell counts above 200 cells/mm3 compared with a protease inhibitor (PI)-based regimen in highly immunosuppressed patients naive to therapy.
The results from this study support the use of Sustiva in protease inhibitor sparing regimens for patients with low CD4 counts, high viral loads, and opportunistic infections.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2002-09-02)
More Articles from AIDS Weekly
- Adverse Drug Effects
Drug eruption study yields surprising results - HIV/AIDS Vertical Transmission
Short-course nevirapine doesn't improve standard preventive therapy - Drug Resistance
UCSD study shows increased transmission of drug-resistant HIV infection - HIV-associated Nephropathy
Viral Nef protein triggers podocyte growth and proliferation - HIV/AIDS Therapy
Novel technique enables single-cell latency analysis - AIDS Therapy
T-20 administration has little impact on daily activities of patients after 8 weeks of treatment - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
